CSRxP: MISGUIDED REBATE RULE A BIG PHARMA BAILOUT PAID FOR BY AMERICAN SENIORS & TAXPAYERS

Rebate Rule Will Increase Premiums for Medicare Part D Beneficiaries, Do Nothing to Lower Drug Prices and Pad Drug Companies’ Bottom Line

Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued a statement Friday after the Trump Administration announced it will publish a final rule aimed at eliminating prescription drug rebates in Medicare Part D.

“The Big Pharma-backed Rebate Rule is a misguided proposal that the administration’s own actuaries found would do nothing to lower drug prices while increasing premiums on Medicare Part D beneficiaries, costing taxpayers more than $200 billion and handing drug companies a more than $100 billion bailout,” said CSRxP executive director Lauren Aronson. “CSRxP looks forward to working with the next administration and lawmakers to halt and reverse implementation of this disastrous policy in order to focus drug pricing efforts instead on market-based solutions to increase transparency, boost competition and hold Big Pharma accountable.”

Get The Facts on the Rebate Rule

Learn more about the misguided Rebate Rule HERE.

Learn more about market-based solutions to hold Big Pharma accountable and lower prescription drug prices HERE.

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.